Goldman Sachs has initiated coverage of generic pharmaceutical stocks, highlighting the sector's strong long-term potential despite recent volatility. Analyst Matt Dellatorre points to a mix of ...

Goldman Sachs lowered its forecast for the total market for anti-obesity drugs through the end of the decade. Asad Haider, head of the healthcare business unit within Goldman Sachs Research, now ...

Eli Lilly and Company (NYSE:LLY) is one of the top stocks to buy and hold forever. The company’s strength lies in its strong moat from a patent-protected drug pipeline and diabetes/obesity leadership.

AstraZeneca PLC (NASDAQ:AZN) ranks among the most undervalued NASDAQ stocks to buy now. Goldman Sachs maintained its Conviction Buy rating on AstraZeneca PLC (NASDAQ:AZN) and boosted its price target ...

The U.S. Centers for Medicare & Medicaid Services (CMS) on Monday issued a draft guidance for public comment on the third cycle of negotiations under the Medicare Drug Price Negotiation Program ...